Clinic Roundup
• Peregrine Pharmaceuticals Inc., of Tustin, Calif., said it reached an agreement with the FDA on the design of a single registration trial testing Cotara in patients with recurrent glioblastoma multiforme.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.